Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
NEW YORK - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company with a market capitalization of $10.87 million, announced positive interim results from the open-label portion of its Phase 2a clinical trial, CLEER-001, evaluating HT-001 for the treatment of pruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors, commonly used in cancer treatments. The company’s stock has shown strong momentum, gaining over 19% in the past week.
Patients in the trial experienced a 50% reduction in the severity of pruritus, with mean scores decreasing from 1.6 at the start of the trial to 0.8 by Day 21. Notably, symptom relief was observed rapidly, with mean scores improving to 1.0 by Day 7, and some patients achieving complete resolution of pruritus within the 21-day period. The treatment was also reported to be well tolerated with no serious adverse events related to HT-001. According to InvestingPro, analysts have set price targets ranging from $4 to $5 for the stock, suggesting significant upside potential. Subscribers can access 8 additional ProTips about HOTH’s financial outlook.
Robb Knie, Chief Executive Officer of Hoth Therapeutics, expressed optimism about the findings, stating that they support the potential of HT-001 to provide meaningful relief for cancer patients experiencing EGFR-related pruritus. He emphasized the importance of addressing cutaneous toxicities that can significantly impact patients’ quality of life and potentially interfere with ongoing cancer treatments.
HT-001 is a proprietary, non-steroidal topical formulation being developed to alleviate itching and irritation without the systemic side effects associated with traditional treatments. The ongoing CLEER-001 study includes a randomized, double-blind portion that continues to evaluate the efficacy and safety of the treatment.
The company also acknowledged the departure of board member Mr. Graig Springer, thanking him for his contributions and wishing him success in his future endeavors.
Hoth Therapeutics focuses on developing treatments aimed at improving patient quality of life, particularly for those with high unmet medical needs. The company’s approach includes collaborating with scientists, clinicians, and key opinion leaders to advance pharmaceutical research and development.
This press release contains forward-looking statements about Hoth’s business strategies, regulatory submissions, and product development plans that involve risks, uncertainties, and assumptions. These statements are based on current expectations and are subject to change. The information in this article is based on a press release statement.
In other recent news, Hoth Therapeutics has announced promising preclinical results for its Alzheimer’s drug candidate, HT-ALZ. The compound showed improvements in cognitive functions and reduced neuroinflammation in Alzheimer’s disease models. The company plans to move HT-ALZ into clinical development to evaluate its safety and efficacy in early-stage Alzheimer’s patients. Additionally, Hoth Therapeutics has filed amended patent claims to bolster intellectual property protection for its HT-KIT drug candidate, which targets allergic inflammation and mast cell-related diseases. The company has also initiated a toxicity study in mice to assess the safety profile of HT-KIT, marking a step towards clinical readiness.
In developments related to gastrointestinal stromal tumors (GIST), Hoth Therapeutics reported significant preclinical progress with HT-KIT, demonstrating a reduction in tumor growth and KIT protein expression. This finding is crucial as the company prepares for further preclinical studies and discussions with regulatory bodies for first-in-human trials. Furthermore, Hoth Therapeutics plans to submit an application for Expanded Access for HT-001, aimed at treating skin conditions caused by cancer treatments. This move aligns with the company’s commitment to addressing unmet medical needs and improving patient outcomes.
In a related update, Hoth Therapeutics shared positive clinical findings for HT-001 in treating skin toxicities from EGFR inhibitors, with a case study showing complete resolution of symptoms in a patient. The results will be presented at the upcoming American Academy of Dermatology Annual Meeting. With a Phase 2A clinical trial underway, the company seeks to further evaluate HT-001’s efficacy and safety in a larger patient population.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.